PDCD1 and metastatic melanoma: In a cohort of metastatic melanoma samples from patients treated with pembrolizumab or nivolumab, PFS and response to ICB were positively correlated with increased proportions of CD8+ T cells in tumor biopsies marked by high surface expression of CTLA-4 and PD-1 (145).